No Data
Hanson Pharmaceuticals: Report for the third quarter of 2024
hunan hansen pharmaceutical (002412.SZ) released its performance for the first three quarters, with a net income of 0.131 billion yuan, a year-on-year increase of 19.15%.
hunan hansen pharmaceutical (002412.SZ) released the third quarter report for 2024, in the first three quarters, the company achieved revenue...
hunan hansen pharmaceutical (002412.SZ): net income of 0.131 billion yuan in the first three quarters, a year-on-year increase of 19.15%.
Gelonghui, on October 28th, Hunan Hansen Pharmaceutical (002412.SZ) released its third quarter report for 2024, achieving a revenue of 0.694 billion yuan in the first three quarters, a year-on-year increase of 1.44%; net income attributable to the shareholders of the listed company was 0.131 billion yuan, a year-on-year increase of 19.15%; net income attributable to the shareholders of the listed company after deducting non-recurring gains and losses was 0.123 billion yuan, a year-on-year increase of 19.14%; and the basic earnings per share was 0.2598 yuan.
Hunan Hansen Pharmaceutical Obtains Drug Registration for Diabetes Treatment Tablets
Hunan Hansen Pharmaceutical (002412.SZ): obtained the registration certificate for pharmaceutical Englitazone tablets.
Gelonghui October 23 | Hunan Hansen Pharmaceutical (002412.SZ) announced that the company recently received the "Drug Registration Certificate" for the chemical drug "Engle Net Tablets" issued by the National Medical Products Administration. The product is used for the treatment of type 2 diabetes.
Has Hunan Hansen Pharmaceutical Co., Ltd.'s (SZSE:002412) Impressive Stock Performance Got Anything to Do With Its Fundamentals?
Benign Growth For Hunan Hansen Pharmaceutical Co., Ltd. (SZSE:002412) Underpins Stock's 29% Plummet
